Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins

Table 3 The major side effects potentially attributable to statin therapy

Hepatic toxicity

Muscle toxicity including:

Myopathy (general term referring to any disease of muscles)

Myalgia (muscle ache or weakness without creatine kinase increase) in 1%-3%

Myositis (muscle symptoms with increase creatine kinase levels) in 0.1%

Rhabdomyolysis (muscle symptoms with increase > 10 × the upper limit of normal CK and creatinine elevation, usually associated with brown urine and urinary mioglobina in 0.0005%